Longeveron Inc.
A clinical-stage biotech that turns young adults' bone-marrow stem cells into an injectable therapy, called Lomecel-B, being studied for aging-related conditions like frailty, Alzheimer's disease and a rare childhood heart defect. The company was founded in 2014 and spun out of the University of Miami's stem-cell institute. Its name blends "longevity" with "ever on"—a nod to its mission of helping people live longer, healthier lives.
Granted 286.0K
Granted 536.0K
Granted 900.0K
Granted 536.0K
Granted 536.0K
Granted 250.0K
Granted 36.0K
Granted 36.0K
Granted 36.0K
Granted 36.0K
Granted 36.0K
Granted 36.0K
Granted 36.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Hare JoshuaChief Scientific Officer, Director, 10% owner · 1 transaction | +122.7% | 1.61M | 286.0K | — | — |
| Lehr Paul TGeneral Counsel, Secretary · 3 transactions | +150.3% | 861.4K | 536.0K | — | — |
| Willard Stephen HChief Executive Officer · 5 transactions | — | 789.7K | 900.0K | — | — |
| Agafonova NataliyaChief Medical Officer · 3 transactions | +231% | 716.9K | 536.0K | — | — |
| Blass DevinCTO & SVP of CMC · 3 transactions | +255.6% | 711.7K | 536.0K | — | — |
| Locklear LisaChief Financial Officer · 2 transactions | +103.5% | 465.7K | 250.0K | — | — |
| Soffer RockDirector · 1 transaction | +15.9% | 262.0K | 36.0K | — | — |
| Ungaro UrsulaDirector · 1 transaction | +87.8% | 77.0K | 36.0K | — | — |
| Paletta George A. Jr.Director · 1 transaction | — | 70.0K | 36.0K | — | — |
| Hajjar Roger JosephDirector · 1 transaction | +109.1% | 69.0K | 36.0K | — | — |
| Ascheim DeborahDirector · 1 transaction | — | 36.0K | 36.0K | — | — |
| Cann Leah RushDirector · 1 transaction | — | 36.0K | 36.0K | — | — |
| Desai Arjun JJDirector · 1 transaction | — | 36.0K | 36.0K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.